FDA and FTC endorsement rules for medspa, aesthetic and pharma marketing
Medspa, aesthetic and pharma marketing sits at the intersection of two regulators — the FDA on drug and device claims, the FTC on endorsements and advertising truthfulness — plus state medical boards on the practice-of-medicine layer. This guide walks the FDA drug and device advertising framework, the 2023 FTC endorsement-guide update, the substantiation standards for before-and-after imagery and testimonials, and the review workflow we operate for US aesthetic and pharma accounts.
- The FDA regulates drug and device advertising under 21 USC 352 (misbranding) and 21 CFR 202 (prescription drug advertising). Medspa services use FDA-regulated products (injectables, lasers, energy devices), so claims about those products fall within FDA jurisdiction.
- Off-label promotion of an approved drug or device — promotion of an unapproved indication, dosage, or use — is evidence of misbranding. The scientific-exchange safe harbour does not extend to consumer advertising.
- The FTC Endorsement Guides (updated June 2023) require clear and conspicuous disclosure of material connections at the point of the endorsement. Liability now expressly reaches advertisers, endorsers, and intermediaries such as advertising agencies.
- Before-and-after imagery must be truthful, non-deceptive, obtained with written patient consent, aligned to FDA-approved indications, and screened against platform personal-health policies before publication.
- State medical boards impose an additional layer — testimonial rules, credentialing disclosures, before-and-after retention requirements. What the FDA and FTC allow, a state board can still prohibit.
- Dallas, Texas LLC
- 10-person US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
What we found when we studied 555 US med spas on Google
Patients praise the care almost without exception. The one area where complaints outnumber praise is booking and communication, and that is where most med spas can win.
Full study · 555 US med spas across 20 metros · roughly ±4% nationally · review velocity and themes from a 115-spa subsample · verified against raw data.
Who regulates what — the FDA, FTC and state overlay
The Food and Drug Administration regulates the manufacture and labelling of drugs, biologics and devices under the Federal Food, Drug, and Cosmetic Act. Prescription drug advertising is regulated at 21 CFR 202.1, and device labelling and promotion at 21 CFR 801. Misbranding — including false or misleading labelling or advertising — is prohibited under 21 USC 352.
The Federal Trade Commission regulates advertising truthfulness and endorsements under 15 USC 45. The FTC Endorsement Guides at 16 CFR Part 255 provide the operational framework for testimonials, expert endorsements, influencer marketing and consumer reviews. The 2023 update was the first substantive revision since 2009 and it materially tightened enforcement expectations.
State medical boards regulate the practice of medicine and the advertising conduct of licensed practitioners. Board rules can be stricter than either FDA or FTC — some states restrict specialty designation, some require credential disclosures on every ad, and many restrict testimonials in specific ways.
The off-label line and where medspa marketing crosses it
The FDA approves drugs and devices for specific indications, dosages, routes and populations. A physician may prescribe off-label based on professional judgment. A manufacturer or promoter may not advertise or promote off-label uses in consumer marketing. Doing so is treated as evidence that the product is misbranded under 21 USC 352 because the labelling (which includes advertising) does not bear adequate directions for the promoted use.
Common off-label patterns in medspa marketing
- Advertising a neurotoxin (approved for specific cosmetic indications) for uses not listed in the approved labelling.
- Advertising a soft-tissue filler for anatomical regions or indications outside approved use.
- Advertising a laser or energy device for conditions or body regions not cleared in the 510(k) or PMA.
- Advertising compounded products with marketing claims equivalent to approved drug products.
The scientific-exchange safe harbour
The FDA has recognised a narrow safe harbour for scientific exchange — peer-reviewed publications, medical-conference presentations, and unsolicited responses to healthcare-professional questions. It does not cover consumer advertising, promotional websites, patient-facing social media, or paid influencer content. A blog post targeted at consumers is not scientific exchange.
The 2023 Endorsement Guides revision — what actually changed
The June 2023 revision to 16 CFR Part 255 tightened four areas relevant to healthcare marketing.
1. Material connection disclosure
Any relationship between the endorser and the advertiser that could affect the weight consumers give the endorsement must be clearly and conspicuously disclosed at the point of the endorsement. That means the disclosure appears where the endorsement appears — not in a linked bio, a scrollable footer, or a hover state. Free products, discounts, family relationships, employment, and financial arrangements all qualify as material connections.
2. Liability chain
The revised guides expressly reach advertisers, endorsers, and intermediaries. An advertising agency, a media buyer, or a talent broker who facilitates a non-compliant endorsement is potentially liable in its own right. Contractual language passing all liability to the endorser does not close the loop for the agency.
3. Consumer reviews
Solicited reviews from incentivised customers must disclose the incentive. Fake reviews, review suppression, and review platforms that filter negative feedback are treated as unfair and deceptive practices. The FTC's separate 2024 rule on fake reviews and testimonials (16 CFR Part 465, effective October 2024) adds a distinct civil-penalty basis.
4. Expert endorsements
An expert endorsement must be based on an appropriate examination or testing of the product, and the expert's qualifications must genuinely give the endorsement the value it implies. A physician endorser must have expertise commensurate with the claims made in the endorsement, and the endorsement must rest on evaluation rather than compensation.
Substantiation, consent and the standardised-imagery pattern
Before-and-after imagery is one of the highest-value creative assets in aesthetic marketing and one of the highest-risk. The FTC's substantiation doctrine requires that the depicted results be typical of what a consumer can expect, or that any atypical result be clearly and conspicuously disclosed. The 2023 endorsement-guide revision reinforced that "results not typical" disclaimers must be clear and conspicuous, not buried.
The substantiation checklist
- Standardised lighting, distance, angle, and positioning between before and after.
- No cosmetic differences (makeup, hair styling, jewellery) between shots.
- Documented time interval and treatment protocol.
- Alignment to the FDA-approved indication for the drug or device used.
- Explicit patient written consent for use of the imagery, retained on file.
- Disclosure of any material connection between the patient and the practice (employee, family, discounted service).
- "Individual results may vary" disclosure placed clearly at the point of the imagery.
Sub-category rules that stack on top
Injectables and neurotoxins
Approved indication only. No off-label anatomical region claims. Physician-supervision disclosure required in many states.
Laser and energy devices
Claims aligned to 510(k) or PMA clearance. Fitzpatrick-skin-type disclosures where clinically relevant. No absolute-outcome guarantees.
Compounded products
No promotional claims equivalent to approved drug products. State pharmacy-compounding rules apply.
Weight-loss drugs
Approved indication only. GLP-1 marketing has drawn active FTC and FDA attention. No unapproved compounded-product promotion.
Hormone therapies
Bioidentical vs FDA-approved distinctions carefully drawn. No efficacy claims outside approved labelling. State board rules on prescriber advertising.
Stem cell and regenerative
Unproven regenerative therapies drew a 2019 FDA warning-letter wave and continue to draw enforcement. Only FDA-approved regenerative products may carry efficacy claims.
Where enforcement actually lands
FTC enforcement in the aesthetic and health-adjacent space has focused on unsubstantiated efficacy claims, hidden material connections in influencer campaigns, review manipulation, and endorsement disclosures that do not meet the clear-and-conspicuous standard. The FDA's warning-letter catalogue in the aesthetic and regenerative space repeatedly targets promotional claims that stray outside approved indications and stem-cell providers making unproven efficacy claims.
Enforcement tends to arrive by two paths: consumer complaints that route through the FTC's consumer sentinel database, and competitor-driven complaints via industry-association referral (particularly the ASAPS/ASPS aesthetic groups). Either path can trigger an investigation, and the discovery burden of an investigation typically dwarfs the cost of proactively building the substantiation folder before the ad runs.
Backed by ICG global leadership
Every aesthetic or pharma-marketing engagement runs under senior review from operators who have shipped US medspa, injectable and device-branded campaigns and who have negotiated substantiation folders that survive an FTC subpoena.
Our own tools run inside every engagement
Ichelon Consulting US uses software built by our own product team. Practices can also use most tools on their own, billed in USD.
FDA and FTC endorsement rules — common questions
Are medspa services regulated by the FDA?
The FDA regulates the drugs and devices used; the practice of medicine is state-regulated. Marketing claims about the drug or device are subject to FDA advertising rules.
Can we promote off-label uses of injectables?
Off-label promotion of an approved product is treated as evidence of misbranding. A physician may prescribe off-label; a marketer promoting off-label in consumer advertising creates FDA exposure.
What did the 2023 FTC Endorsement Guides update change?
Tightened material-connection disclosure, expanded liability to intermediaries, clarified clear-and-conspicuous standard, addressed consumer reviews and expert endorsements.
How do we use before-and-after imagery safely?
Standardised protocol, patient consent, alignment to approved indications, platform-policy screening, and a substantiation folder retained on file.
What is a material connection for FTC purposes?
A relationship between endorser and advertiser that could affect the weight consumers give the endorsement — free product, discount, employment, family tie, or financial arrangement.
Do FDA rules apply to social-media influencer content?
Yes. Both FDA and FTC apply the same substantiation and disclosure rules to social-media promotional content.
Ship an FDA- and FTC-defensible marketing program
Book a 30-minute call with the Leadership Team, email the US practice lead, or WhatsApp us in your time zone. Retainers are custom-scoped per engagement · from $499/month.